MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet faces the development of acquired resistance as the major obstacle to long-term disease remission in the clinic. MET (or c-MET) gene am...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiming, Yang, Sen, Wang, Kai, Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588884/
https://www.ncbi.nlm.nih.gov/pubmed/31227004
http://dx.doi.org/10.1186/s13045-019-0759-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588884/
https://www.ncbi.nlm.nih.gov/pubmed/31227004
http://dx.doi.org/10.1186/s13045-019-0759-9

Ejemplares similares